Biotech Startups

PhyCo is a marine biotechnology company producing compostable, seaweed-based bioplastics as alternatives to petroleum plastics used in agriculture and food supply systems. Working with native Canadian seaweed species and in partnership with Indigenous Nations, it targets plastic used in farming operations across Canada.

1 investor

Phyla produces skincare products for acne-prone skin, including a pH-balancing gel cleanser that removes excess oil without irritation. The company focuses on microbiome-conscious formulations recommended by dermatologists.

1 investor

Phyllome grows edible plants engineered to express cyclotide therapeutic peptides, turning them into functional foods with controlled therapeutic dosing as an oral alternative to injected or synthetic drugs. Its pipeline targets analgesic, cholesterol-modulating, and appetite-regulating applications, developed with the University of Queensland's Institute for Molecular Bioscience.

1 investor

Physiomics is a consultancy that applies mathematical modelling and biostatistics to support drug development and clinical trials for pharmaceutical and biotech clients.

1 investor

Phytolon produces natural food colors derived from baker's yeast fermentation technology, offering vivid hues with heat stability and clean label credentials for food manufacturers. The company targets food producers seeking sustainable, cost-effective color solutions across multiple product categories.

1 investor

Phytonix is an industrial biotechnology company that uses genetically engineered cyanobacteria and synthetic biology to convert carbon dioxide emissions and sunlight into sustainable chemicals and fuels, starting with n-butanol as a drop-in gasoline replacement and industrial chemical. It targets the global n-butanol chemical market and co-locates its production with industrial CO2 emitters.

1 investor

Piatrika Biosystems builds genomics and AI-driven software for agriculture, serving seed and agricultural input companies to support molecular breeding, regulatory compliance, and crop development. The company operates R&D and technology teams in Cambridge, U.K. and Hyderabad, India.

1 investor

1 investor

Picodya develops microfluidic diagnostic technology designed to increase access to diagnostic testing worldwide. The company applies its pico technology platform to enable faster, more efficient medical diagnostics for global populations.

1 investor

1 investor

Pilatus Biosciences develops first-in-class antibodies and bifunctional proteins that target metabolic checkpoints to reprogram the immune microenvironment for treating cancer and immune-related diseases. Its lead candidate, an anti-CD36 monoclonal antibody, is in Phase 1 clinical trials for advanced solid tumors.

1 investor

Latent Labs develops AI tools for drug discovery and design, enabling biotech and pharmaceutical companies to accelerate therapeutic molecule identification. The platform democratizes access to advanced generative AI models, reducing the need for in-house AI development capabilities.

1 investor

PinCell is a pre-clinical stage biotech company developing first-in-class anti-inflammatory therapies that target novel pathological pathways for dermatological diseases, with a focus on orphan skin disorders with high unmet medical need.

1 investor

Pine Tree Therapeutics develops therapies based on targeted protein degradation, with a focus on addressing drug resistance. Its work centers on oncology and related disease areas.

1 investor

PinkDx is a diagnostics company developing tests, led by a leadership team spanning scientific, medical, and business functions.

1 investor

Pinova Therapeutics is developing a ready-to-use, low-cost Naloxone product with an enhanced dosage form intended for over-the-counter access. It aims to reduce cost and access barriers to opioid overdose reversal medication for consumers and institutions.

1 investor

Pipeline Pharma provides a database and intelligence platform for pharmaceutical companies to analyze competitive landscapes, regulatory pipelines, and sourcing opportunities across drug molecules and therapeutic areas. The platform enables investment decisions, portfolio optimization, and commercial supplier comparisons through access to over 82,500 clinical trial dossiers globally.

1 investor

Pixl.bio produces iPSC-derived hepatic stellate cells for liver disease modeling and fibrosis research. The cells are used in studies of metabolic-associated fatty liver disease (MASLD), steatohepatitis, and chronic liver injury.

1 investor

Place Genomics develops DNA nanotechnology and next-generation sequencing (NGS) sample preparation technologies for genomic research and precision medicine applications. The company focuses on genomics innovations for use in health and medicine.

1 investor

PLAIO offers demand planning software that uses machine learning and statistical models to forecast future demand by analyzing historical data and market inputs, serving businesses across industries including pharmaceuticals. The platform consolidates forecasts and purchase orders while maintaining human oversight through manual overrides and audit trails, and integrates with ERP systems like SAP.

1 investor

Planasa breeds and develops superior berry varieties including blueberries, raspberries, strawberries, and blackberries, along with garlic, asparagus, and avocado, using traditional and modern breeding methods for distribution through nursery operations to growers worldwide.

1 investor

Planet Biotech develops plant biotechnology products and active ingredients for sustainable agriculture that increase crop resilience to drought and heat stress. The company serves farmers and agribusiness by commercializing science-based solutions to address food security and climate change impacts.

1 investor

Planetarians develops food technology to produce affordable meat alternatives, drawing on protein chemistry and process engineering to bring products to market. The company operates in the foodtech and alternative protein space.

1 investor

Plant Health Care develops biological crop products, including patented harpin-based proteins and peptides marketed as "vaccines for plants" that act as biostimulants and boost plants' natural disease resistance to improve yield and quality. It sells products such as Harpinαß and PHC279 to farmers worldwide through specialist distributors and its PREtec platform, and is a wholly owned subsidiary of PI Industries Ltd of India.

1 investor